persmedРоссийский журнал персонализированной медициныRussian Journal for Personalized Medicine2782-38062782-3814ФОНД АЛМАЗОВА10.18705/2782-3806-2022-2-2-63-71persmed-46Research ArticleОБЗОРЫREVIEWERSПатология иммунного надзора как основа патогенеза системной красной волчанкиImpaired immune function in the pathogenesis of systemic lupus erythematosusКучинскаяЕ. М.КuchinskayaЕ. М.

Екатерина Михайловна Кучинская, к. м. н., врач-ревматолог

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова»

амбулаторно-консультативное отделение для детей

197341

ул. Аккуратова, д. 2

Санкт-Петербург

Ekaterina M. Kuchinskaya, PhD, rheumatologist

Federal State Budgetary Institution "V. A. Almazov National Medical Research Center"

outpatient advisory department for children

197341

Akkuratova str., 2

Saint-Petersburg

kuchinskaya.link@gmail.comКостикМ. М.KostikM. M.

Михаил Михайлович Костик, д.м.н., профессор

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова»

Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный педиатрический медицинский университет»

кафедра госпитальной педиатрии

Санкт-Петербург

Mikhail M. Kostik, MD, Professor

Federal State Budgetary Institution "V. A. Almazov National Medical Research Center"

Federal State Budgetary Educational Institution of Higher Education "St. Petersburg State Pediatric Medical University"

Department of Hospital Pediatrics

Saint-Petersburg

ЛюбимоваН. А.LyubimovaN. А.

Наталья Андреевна Любимова, к. м. н., врач-ревматолог

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова»

отделение педиатрии и медицинской реабилитации для детей № 1

Санкт-Петербург

Natalia A. Lyubimova, PhD, rheumatologist

Federal State Budgetary Institution "V. A. Almazov National Medical Research Center"

Department of Pediatrics and Medical Rehabilitation for children No. 1

Saint-Petersburg

Министерство здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research CentreRussian FederationМинистерство здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research Centre; Saint-Petersburg State Pediatric Medical UniversityRussian Federation202202062022226371Copyright © Кучинская Е.М., Костик М.М., Любимова Н.А., 20222022Кучинская Е.М., Костик М.М., Любимова Н.А.Кuchinskaya Е.М., Kostik M.M., Lyubimova N.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://persmed.elpub.ru/jour/article/view/46

   Системная красная волчанка (СКВ) — гетерогенное иммунопатологическое заболевание, характеризующееся вариабельными клиническими проявлениями и сложным, не до конца изученным патогенезом. Важную роль в нем играют различные формы клеточной смерти, ведущие к презентации аутоантигена иммунокомпетентным клеткам, выработке провоспалительных цитокинов и дисбалансу между эффекторным и регуляторным звеном клеточного иммунитета. Изучение путей патогенеза СКВ является ключом к поиску потенциальных точек приложения для таргетной терапии. Настоящий обзор кратко освещает современные знания о патогенетических механизмах этого заболевания, включая данные новейших научных исследований.

   Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by variable clinical manifestations and a complex pathogenesis not fully understood at the moment. Various forms of cell death play an important role, eventually leading to the presentation of the autoantigen to immunocompetent cells, the production of pro-inflammatory cytokines, and an imbalance between the effectors and regulators of cellular immunity. The study of SLE pathogenesis pathways includes the search for potential objects for targeted therapy. This review briefly discusses the current knowledge about the pathogenetic mechanisms of this disease, including the researches latest to-date.

аутоиммунные заболеванияинфламмасомаклеточная смертьпатогенезсистемная красная волчанкатаргетная терапияautoimmune diseasescell deathinflammasomepathogenesissystemic lupus erythematosustargeted therapyReferencesTsokos G. C. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020; 21: 605–614.Tsokos G. C. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020; 21: 605–614.Nagata S. Apoptosis and clearance of apoptotic cells. Annual Review of Immunology. 2018; 36: 489–517.Nagata S. Apoptosis and clearance of apoptotic cells. Annual Review of Immunology. 2018; 36: 489–517.Ning X., Wang Y., Jing M., et al. Apoptotic caspases suppress type I interferon production via the cleavage of cGAS, MAVS, and IRF3. Molecular Cell. 2019; 74 (1): 19–31.Ning X., Wang Y., Jing M., et al. Apoptotic caspases suppress type I interferon production via the cleavage of cGAS, MAVS, and IRF3. Molecular Cell. 2019; 74 (1): 19–31.Munoz L. E., Chaurio R. A., Gaipl U. S., et al. MoMa from patients with systemic lupus erythematosus show altered adhesive activity. Autoimmunity. 2009; 42 (4): 269–71.Munoz L. E., Chaurio R. A., Gaipl U. S., et al. MoMa from patients with systemic lupus erythematosus show altered adhesive activity. Autoimmunity. 2009; 42 (4): 269–71.Smith J. P., Burton G. F., Tew J. G., et al. Tingible body macrophages in regulation of germinal center reactions. Dev Immunol. 1998; 6 (3–4): 285–94.Smith J. P., Burton G. F., Tew J. G., et al. Tingible body macrophages in regulation of germinal center reactions. Dev Immunol. 1998; 6 (3–4): 285–94.Baumann I., Kolowos W., Voll R. E., et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum. 2002; 46 (1): 191–201.Baumann I., Kolowos W., Voll R. E., et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum. 2002; 46 (1): 191–201.Tajbakhsh A., Gheibi H. S., Butler A. E., et al. Effect of soluble cleavage products of important receptors/-ligands on efferocytosis: their role in inflammatory, au-toimmune and cardiovascular disease. Ageing Research Reviews. 2019; 50: 43–57.Tajbakhsh A., Gheibi H. S., Butler A. E., et al. Effect of soluble cleavage products of important receptors/-ligands on efferocytosis: their role in inflammatory, au-toimmune and cardiovascular disease. Ageing Research Reviews. 2019; 50: 43–57.Satoh M., Reeves W. H. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med. 1994; 180 (6): 2341–6.Satoh M., Reeves W. H. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med. 1994; 180 (6): 2341–6.Mattecka S., Bock C., Vogt B., et al. CRP and SAP from different species have different membrane ligand specificities. Autoimmunity. 2013; 46 (5): 347–50.Mattecka S., Bock C., Vogt B., et al. CRP and SAP from different species have different membrane ligand specificities. Autoimmunity. 2013; 46 (5): 347–50.Yang F., He Y., Zhai Z., et al. Programmed cell death pathways in the pathogenesis of systemic lupus erythematosus. J Immunol Res. 2019; 3638562.Yang F., He Y., Zhai Z., et al. Programmed cell death pathways in the pathogenesis of systemic lupus erythematosus. J Immunol Res. 2019; 3638562.Lee K. H., Kronbichler A., Park D. D., et al. Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review. Autoimmunity Reviews. 2017; 16 (11): 1160–1173.Lee K. H., Kronbichler A., Park D. D., et al. Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review. Autoimmunity Reviews. 2017; 16 (11): 1160–1173.Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nature Reviews Immunology. 2018; 18 (2): 134–147.Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nature Reviews Immunology. 2018; 18 (2): 134–147.Kahlenberg J. M., Carmona-Rivera C., Smith C. K., et al. Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. Journal of Immunology. 2013; 190 (3): 1217–1226.Kahlenberg J. M., Carmona-Rivera C., Smith C. K., et al. Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. Journal of Immunology. 2013; 190 (3): 1217–1226.Hakkim A., Furnrohr B. G., Amann K., et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A. 2010; 107 (21): 9813–8.Hakkim A., Furnrohr B. G., Amann K., et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A. 2010; 107 (21): 9813–8.Pieterse E., van der Vlag J. Breaking immunological tolerance in systemic lupus erythematosus. Front Immunol. 2014; 5: 164.Pieterse E., van der Vlag J. Breaking immunological tolerance in systemic lupus erythematosus. Front Immunol. 2014; 5: 164.Mahajan A., Herrmann M., Muñoz L. E. Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE. Front Immunol. 2016; 7: 35.Mahajan A., Herrmann M., Muñoz L. E. Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE. Front Immunol. 2016; 7: 35.Lindau D., Mussard J., Rabsteyn A., et al. TLR9 independent interferon alpha production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen. Ann Rheum Dis. 2014; 73 (12): 2199–207.Lindau D., Mussard J., Rabsteyn A., et al. TLR9 independent interferon alpha production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen. Ann Rheum Dis. 2014; 73 (12): 2199–207.Munoz L. E., Janko C., Grossmayer G. E., et al. Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum. 2009; 60 (6): 1733–42.Munoz L. E., Janko C., Grossmayer G. E., et al. Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum. 2009; 60 (6): 1733–42.Banchereau J., Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity. 2006; 25 (3): 383–92.Banchereau J., Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity. 2006; 25 (3): 383–92.Wu Y. W., Tang W., Zuo J. P. Toll-like receptors: potential targets for lupus treatment. Acta Pharmacol Sin. 2015; 36 (12): 1395–407.Wu Y. W., Tang W., Zuo J. P. Toll-like receptors: potential targets for lupus treatment. Acta Pharmacol Sin. 2015; 36 (12): 1395–407.Park J. S., Svetkauskaite D., He Q., et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2004; 279: 7370–7.Park J. S., Svetkauskaite D., He Q., et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2004; 279: 7370–7.Komatsuda A., Wakui H., Iwamoto K., et al. Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol. 2008; 152: 482–7.Komatsuda A., Wakui H., Iwamoto K., et al. Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol. 2008; 152: 482–7.Kahlenberg J. M., Thacker S. G., Berthier C. C., et al. Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol. 2011; Dec 1; 187 (11): 6143–56.Kahlenberg J. M., Thacker S. G., Berthier C. C., et al. Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol. 2011; Dec 1; 187 (11): 6143–56.Shin M. S., Kang Y., Lee N., et al. U1-small nuclear ribonucleoprotein activates the NLRP3 inflammasome in human monocytes. The journal of immunology. 2012; May 15; 188 (10): 4769–75.Shin M. S., Kang Y., Lee N., et al. U1-small nuclear ribonucleoprotein activates the NLRP3 inflammasome in human monocytes. The journal of immunology. 2012; May 15; 188 (10): 4769–75.Wang Y., Gao W., Shi X., et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017; 547 (7661): 99–103.Wang Y., Gao W., Shi X., et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017; 547 (7661): 99–103.Benoit M. E., Clarke E. V., Morgado P., et al. Complement protein C1q directs macrophage polarization and limits inflammasome activity during the uptake of apoptotic cells. The Journal of Immunology. 2012; 188 (11): 5682–93.Benoit M. E., Clarke E. V., Morgado P., et al. Complement protein C1q directs macrophage polarization and limits inflammasome activity during the uptake of apoptotic cells. The Journal of Immunology. 2012; 188 (11): 5682–93.Hatef M. R., Sahebari M., Rezaieyazdi Z., et al. Stronger correlation between interleukin 18 and soluble FAS in lupus nephritis compared with mild lupus. ISRN rheumatology. 2013; 850851.Hatef M. R., Sahebari M., Rezaieyazdi Z., et al. Stronger correlation between interleukin 18 and soluble FAS in lupus nephritis compared with mild lupus. ISRN rheumatology. 2013; 850851.Sarhan J., Liu B. C., Muendlein H. I., et al. Constitutive interferon signaling maintains critical threshold of MLKL expression to license necroptosis. Cell Death and Differentiation. 2019; 26 (2): 332–347.Sarhan J., Liu B. C., Muendlein H. I., et al. Constitutive interferon signaling maintains critical threshold of MLKL expression to license necroptosis. Cell Death and Differentiation. 2019; 26 (2): 332–347.Lawlor K. E., Khan N., Mildenhall A., et al. RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. Nature Communications. 2015; vol. 6, no. 1, p. 6282.Lawlor K. E., Khan N., Mildenhall A., et al. RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. Nature Communications. 2015; vol. 6, no. 1, p. 6282.Fu R., Xia Y., Li M., et al. Pim-1 as a Therapeutic Target in Lupus Nephritis. Arthritis Rheumatol. 2019; 71: 1308–1318.Fu R., Xia Y., Li M., et al. Pim-1 as a Therapeutic Target in Lupus Nephritis. Arthritis Rheumatol. 2019; 71: 1308–1318.Sang A., Zheng Y. Y., Morel L. Contributions of B-cells to lupus pathogenesis. Mol Immunol. 2014; 62 (2): 329–38.Sang A., Zheng Y. Y., Morel L. Contributions of B-cells to lupus pathogenesis. Mol Immunol. 2014; 62 (2): 329–38.Chan T. D., Wood K., Hermes J. R., et al. Elimination of germinal-centerderived self-reactive B cells is governed by the location and concentration of self-antigen. Immunity. 2012; 37: 893–904.Chan T. D., Wood K., Hermes J. R., et al. Elimination of germinal-centerderived self-reactive B cells is governed by the location and concentration of self-antigen. Immunity. 2012; 37: 893–904.Scharer C. D., Blalock E. L., Mi T., et al. Epigenetic programming underpins B cell dysfunction in human SLE. Nat Immunol. 2019; 20: 1071–1082.Scharer C. D., Blalock E. L., Mi T., et al. Epigenetic programming underpins B cell dysfunction in human SLE. Nat Immunol. 2019; 20: 1071–1082.Tsai F., Homan P. J., Agrawal H., et al. Bim suppresses the development of SLE by limiting myeloid inflammatory responses. J Exp Med. 2017; 214 (12): 3753–3773.Tsai F., Homan P. J., Agrawal H., et al. Bim suppresses the development of SLE by limiting myeloid inflammatory responses. J Exp Med. 2017; 214 (12): 3753–3773.Luo S., Long H., Lu Q. Recent advances in understanding pathogenesis and therapeutic strategies of Systemic Lupus Erythematosus. Int Immunopharmacol. 2020; 89 (Pt A): 107028.Luo S., Long H., Lu Q. Recent advances in understanding pathogenesis and therapeutic strategies of Systemic Lupus Erythematosus. Int Immunopharmacol. 2020; 89 (Pt A): 107028.Grammer A. C., Lipsky P. E. B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther. 2003; 5 (Suppl 4): S22–7.Grammer A. C., Lipsky P. E. B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther. 2003; 5 (Suppl 4): S22–7.Su K., Yang H., Li X., et al. Expression profile of FcγRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. The Journal of Immunology. 2007; 178 (5): 3272–3280.Su K., Yang H., Li X., et al. Expression profile of FcγRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. The Journal of Immunology. 2007; 178 (5): 3272–3280.Zhou X., Cheng F., Qi Y., et al. FCGR2B and FCRLB gene polymorphisms associated with IgA nephropathy. PLoS ONE. 2013; 8 (4): e61208.Zhou X., Cheng F., Qi Y., et al. FCGR2B and FCRLB gene polymorphisms associated with IgA nephropathy. PLoS ONE. 2013; 8 (4): e61208.Hu W., Zhang Y., Sun X., et al. FcγRIIB-I232T polymorphic change allosterically suppresses ligand binding. Elife. 2019; 8: e46689.Hu W., Zhang Y., Sun X., et al. FcγRIIB-I232T polymorphic change allosterically suppresses ligand binding. Elife. 2019; 8: e46689.La Cava A. Tregs in SLE: an Update. Curr Rheumatol Rep. 2018; Feb 21; 20 (2): 6.La Cava A. Tregs in SLE: an Update. Curr Rheumatol Rep. 2018; Feb 21; 20 (2): 6.Han X., Vesely M. D., Yang W., et al. PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus. Science translational medicine. 2019; 11 (522).Han X., Vesely M. D., Yang W., et al. PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus. Science translational medicine. 2019; 11 (522).

The authors declare that there are no conflicts of interest present.